The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients

The second generation tyrosine kinase inhibitor (TKI) dasatinib is a clinically approved drug for chronic myeloid leukemia (CML) as well as Ph(+) acute lymphoblastic leukemia. In addition to its antileukemic effects, dasatinib was shown to impact on normal hematopoiesis and cells of the immune syste...

Descripción completa

Detalles Bibliográficos
Autores principales: Schubert, Claudia, Chatain, Nicolas, Braunschweig, Till, Schemionek, Mirle, Feldberg, Kristina, Hoffmann, Melanie, Dufva, Olli, Mustjoki, Satu, Brümmendorf, Tim H., Koschmieder, Steffen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471007/
https://www.ncbi.nlm.nih.gov/pubmed/28423730
http://dx.doi.org/10.18632/oncotarget.16152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471007/
https://www.ncbi.nlm.nih.gov/pubmed/28423730
http://dx.doi.org/10.18632/oncotarget.16152

Ejemplares similares